Olatoyosi Odenike to Mutation
This is a "connection" page, showing publications Olatoyosi Odenike has written about Mutation.
Connection Strength
0.999
-
The dawn of the molecular era of the myelodysplastic syndromes. N Engl J Med. 2011 Jun 30; 364(26):2545-6.
Score: 0.182
-
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
Score: 0.179
-
Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
Score: 0.087
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.084
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
Score: 0.078
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.061
-
Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies. Curr Hematol Malig Rep. 2015 Jun; 10(2):112-7.
Score: 0.060
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.053
-
Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010 Jan; 10(1):23-36.
Score: 0.041
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.026
-
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica. 2021 09 01; 106(9):2397-2404.
Score: 0.023
-
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11.
Score: 0.023
-
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
Score: 0.022
-
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
Score: 0.022
-
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.
Score: 0.022
-
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med. 2015 Sep 03; 373(10):920-8.
Score: 0.015
-
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109.
Score: 0.012
-
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503.
Score: 0.008